Business ❯ Pharmaceuticals ❯ Drug Development

Regulatory Affairs

New Drug Application FDA Approval Market Strategy European Medicines Agency Global Access Strategies Biologics License Application FDA Communications

Corcept Faces Securities Class Action Over Relacorilant Disclosures as Firms Rally Investors Before April 21 Deadline

Plaintiffs say Corcept overstated relacorilant’s approval prospects in the face of FDA concerns.

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

U.S. to Buy Lenacapavir PrEP Doses to Reach Up to 2 Million People by 2028